AstraZeneca has decided to invest USD 3.5 billion in the United States focused on expanding the company’s research and manufacturing footprint by the end of 2026.

This includes USD 2 billion of new investment creating more than a thousand new, highly skilled jobs contributing to the growth of the US economy.

AstraZeneca’s expanding footprint in the US includes a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next-generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts, and a specialty manufacturing facility in Texas

Pascal Soriot, Chief Executive Officer, AstraZeneca, said, “Our multibillion-dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”

These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve USD 80 billion in total revenue by 2030 as set out in May this year.

A key element of our strategy is accelerating the company’s development in the United States. The US is AstraZeneca’s largest market, generating 44 percent of its Total Revenue.